Chronic myeloid leukaemia: Biology and therapy

Wang, Yun; Liang, Zhi-jian; Gale, Robert Peter; Liao, Hua-ze; Ma, Jun; Gong, Tie-jun; Shao, Ying-qi; Liang, Yang

doi:10.1016/j.blre.2024.101196

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?

Lipton

2024

American J Hematol

View full text Add to dashboard Cite

Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?

Lipton

2024

American J Hematol

View full text Add to dashboard Cite

Introduction to Neoplasia

Argyris,

Herzberg

2024

Reference Module in Biomedical Sciences

View full text Add to dashboard Cite

Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia

Chavaro-Francisco,

Hernández-Zavala,

Bravo-Cidro

et al. 2024

Genes

View full text Add to dashboard Cite

Current therapy in chronic myeloid leukemia (CML) has improved patient life expectancy close to that of healthy individuals. However, molecular alterations other than BCR::ABL1 fusion gene in CML are barely known. MicroRNAs are important regulators of gene expression, and variants in some of the components of microRNA biosynthesis pathways have been associated with genetic susceptibility to different types of cancer. Thus, the aim of this study was to evaluate the association of variants located in genes involved in the biogenesis of microRNAs with susceptibility to CML. Fifteen variants in eight genes involved in the biogenesis of miRNAs were genotyped in 296 individuals with CML and 485 healthy participants using TaqMan probes. The association of gene variants with CML and clinical variables was evaluated by a Chi-square test, and odds ratios and 95% confidence intervals were estimated by logistic regression. The variant rs13078 in DICER1 was significantly higher among CML individuals than in healthy participants. In addition, the variants rs7813 and rs2740349 were significantly associated with worse prognosis, according to their Hasford scores, whereas the rs2740349 variant was also associated with a later age at diagnosis. These findings suggest that variants in components of the microRNA biogenesis pathway could be involved in CML genetic risk.

show abstract

Chronic myeloid leukaemia: Biology and therapy

Cited by 3 publications

References 194 publications

Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?

Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?

Introduction to Neoplasia

Gene Variants in Components of the microRNA Processing Pathway in Chronic Myeloid Leukemia

Contact Info

Product

Resources

About